Analysis of the world literature shows that AB0-incompatible kidney transplantation is an effective method of treating patients with end-stage renal failure. However, such treatment is possible only under certain conditions. They are: determination of anti-A/B antibodies titer in the recipient’s blood and their elimination before the implantation of donor organ. Antibodies of the AB0 system — α and β are normal (natural) for humans. They belong to full antibodies — agglutinins. One of the methods for their determination is using the salt agglutination reaction. It does not require any special financial expenses, it is less accurate and takes from 4 to 6 hours to complete. Another method is microgel technology: it is more expensive, but more accurate, its performance takes less time and the test results can be saved for a long time. Several methods are used to eliminate anti-A/B antibodies. Plasmapheresis: the advantages are that, in addition to anti-A/B antibodies, other donor-specific antibodies, such as anti-HLA, are also removed in a potential recipient, and the content of the complement system proteins involved in damage to the graft is reduced in the blood. The disadvantage is that the removed plasma should be replaced, and that is possible only with donor plasma of the fourth (AB) blood group and albumin, which may cause allergic reactions, infectious complications and blood clotting disorders. Unlike plasma exchange, the method of cascade plasmapheresis allows selectively remove only the part of patient’s plasma that contains immunoglobulins. It requires less replacement volumes of donor plasma and albumin. However, the risks of this method compared to plasmapheresis remain, although to a lesser extent. The method of specific anti-A/B immunoadsorption is used with special sorbent columns. The advantages of this method of removing circulating anti-blood group antibodies are high efficiency, no need to replace the lost protein with fresh frozen plasma or albumin. However, this method requires specialized expensive equipment and does not remove anti-HLA antibodies, if any, from the recipient’s blood.
end-stage renal failure; AB0-incompatible kidney transplantation; microgel technology; salt agglutination method; plasmapheresis; cascade plasmapheresis; immunoadsorption; review
Sugiyama K, Hyodo Y, Aikawa A. Evaluation of blood group antibodies in ABO-incompatible living-donor kidney transplantation. Int J Urol. 2015 Oct;22(10):931-6. doi: 10.1111/iju.12845.
Schwenger V, Morath C. Immunoadsorption in nephrology and kidney transplantation. Nephrol Dial Transplant. 2010 Aug;25(8):2407-13. doi: 10.1093/ndt/gfq264.
Ministry of Нealth of Ukraine; Kyiv Research Institute of Blood Transfusion of the National Academy of Medical Sciences of Ukraine; Lviv Research Institute of Blood Pathology and Transfusion Medicine of the National Academy of Medical Sciences of Ukraine. Vyznachennja grup krovi za systemoju AV0, rezus ta imunyh antytil: Instrukcija [Determination of blood groups using the AB0, Rhesus and Immuno-antibodies system: Instructions]. Ky'v; 1999. 1-47 pp. (in Ukrainian).
Lapovec' LJe, Lucyk BD. Laboratorna imunologija [Laboratory immunology]. Kyiv; 2004. 64-66 pp. (in Ukrainian).
Got'e SV, Porunova AK, Morozova VV, Tsirul'nikova IE, Tsirul'nikova OM. Sposob titrovaniia gruppovykh antitel sistemy AV0 [The method of titration of group antibodies of the AB0 system]. Patent RU 2526820, 2014. (in Russian).
Russian journal of hematology and transfusiology. 1989;(10).
Park ES, Jo KI, Shin JW, et al. Comparison of total and IgG ABO antibody titers in healthy individuals by using tube and column agglutination techniques. Ann Lab Med. 2014 May;34(3):223-9. doi: 10.3343/alm.2014.34.3.223.
Wahrmann M, Schiemann M, Marinova L, et al. Anti-A/B antibody depletion by semiselective versus ABO blood group-specific immunoadsorption. Nephrol Dial Transplant. 2012 May;27(5):2122-9. doi: 10.1093/ndt/gfr610.
Muramatsu M, Gonzalez HD, Cacciola R, Aikawa A, Yaqoob MM, Puliatti C. ABO incompatible renal transplants: good or bad? World J Transplant. 2014 Mar 24;4(1):18-29. doi: 10.5500/wjt.v4.i1.18.
Pierson RN 3rd, Loyd JE, Goodwin A, et al. Successful management of an ABO-mismatched lung allograft using antigen-specific immunoadsorption, complement inhibition, and immunomodulatory therapy. Transplantation. 2002 Jul 15;74(1):79-84. doi: 10.1097/00007890-200207150-00014.
Rabitsch W, Knöbl P, Greinix H, et al. Removal of persisting isohaemagglutinins with Ig-Therasorb immunoadsorption after major ABO-incompatible non-myeloablative allogeneic haematopoietic stem cell transplantation. Nephrol Dial Transplant. 2003 Nov;18(11):2405-8. doi: 10.1093/ndt/gfg364.
Chirnside A, Urbaniak SJ, Prowse CV, Keller AJ. Coagulation abnormalities following intensive plasma exchange on the cell separator. II. Effects on factors I, II, V, VII, VIII, IX, X and antithrombin III. Br J Haematol. 1981 Aug;48(4):627-34. doi: 10.1111/j.1365-2141.1981.00627.x.
Domen RE, Kennedy MS, Jones LL, Senhauser DA. Hemostatic imbalances produced by plasma exchange. Transfusion. 1984 Jul-Aug;24(4):336-9. doi: 10.1046/j.1537-2995.1984.24484275577.x.
Huestis DW. Risks and safety practices in hemapheresis procedures. Arch Pathol Lab Med. 1989 Mar;113(3):273-8.
Moysyuk YG, Sushkov AI, Pulkova NV, et al. The first Russian experience of abo-incompatible kidney transplantation with antigen-specific immunoadsorption. Vestnik transplantologii i iskusstvennyh organov. 2011;13(4):6-18. (in Russian).
Kanellopoulou T, Kostelidou T. Literature review of apheresis procedures performed perioperatively in cardiac surgery for ASFA category indications. J Clin Apher. 2019 Aug;34(4):474-479. doi: 10.1002/jca.21676.
Agishi T, Kaneko I, Hasuo Y, et al. Double filtration plasmapheresis. Ther Apher. 2000 Feb;4(1):29-33.
Takahashi K. Accommodation in ABO-incompatible kidney transplantation: why do kidney grafts survive? Transplant Proc. 2004 Mar;36(2 Suppl):193S-196S. doi: 10.1016/j.transproceed.2004.01.070.
Higgins R, Lowe D, Hathaway M, et al. Double filtration plasmapheresis in antibody-incompatible kidney transplantation. Ther Apher Dial. 2010 Aug 1;14(4):392-9. doi: 10.1111/j.1744-9987.2010.00821.x.
Hanafusa N, Kondo Y, Suzuki M, Nakao A, Noiri E, Fujita T. Double filtration plasmapheresis can decrease factor XIII Activity. Ther Apher Dial. 2007 Jun;11(3):165-70. doi: 10.1111/j.1744-9987.2007.00433.x.
Lin SM, Yeh JH, Lee CC, Chiu HC. Clearance of fibrinogen and von Willebrand factor in serial double-filtration plasmapheresis. J Clin Apher. 2003;18(2):67-70. DOI: 10.1002/jca.10052.
Belàk M, Borberg H, Jimenez C, Oette K. Technical and clinical experience with protein A immunoadsorption columns. Transfus Sci. 1994 Dec;15(4):419-22. doi: 10.1016/0955-3886(94)90174-0.
Belák M, Widder RA, Brunner R, Borberg H, Haupt WF. Immunoadsorption with protein A sepharose or silica. Lancet. 1994 Mar 26;343(8900):792-3. doi: 10.1016/s0140-6736(94)91868-6.
Tydén G, Kumlien G, Efvergren M. Present techniques for antibody removal. Transplantation. 2007 Dec 27;84(12 Suppl):S27-9. doi: 10.1097/01.tp.0000296102.94695.c0.
Tydén G, Kumlien G, Fehrman I. Successful ABO-incompatible kidney transplantations without splenectomy using antigen-specific immunoadsorption and rituximab. Transplantation. 2003 Aug 27;76(4):730-1. doi: 10.1097/01.TP.0000078622.43689.D4.
Terman DS, Petty D, Harbeck R, Carr RI, Buffaloe G. Specific removal of DNA antibodies in vivo by extracorporeal circulation over DNA immunobilized in collodion charcoal. Clin Immunol Immunopathol. 1977 Jul;8(1):90-6.
Rydberg L, Nyberg G, Attman PO, Mjörnstedt L, Tufveson G, Blohme I. Characterization of the anti-A antibody binding in an ABO-incompatible living donor renal transplantation. Nephrol Dial Transplant. 1994;9(8):1162-5. doi: 10.1093/ndt/9.8.1162. doi: 10.1016/j.transproceed.2004.08.142.
Tanabe K, Tokumoto T, Ishida H, et al. Excellent outcome of ABO-incompatible living kidney transplantation under pretransplantation immunosuppression with tacrolimus, mycophenolate mofetil, and steroid. Transplant Proc. 2004 Sep;36(7):2175-7. doi: 10.1016/j.transproceed.2004.08.142.
Terman DS, Buffaloe G, Mattioli C, et al. Extracorporeal immunoadsorption: initial experience in human systemic lupus erythematosus. Lancet. 1979 Oct 20;2(8147):824-7. doi: 10.1016/s0140-6736(79)92177-9.
Tanabe K. Double-filtration plasmapheresis. Transplantation. 2007 Dec 27;84(12 Suppl):S30-2. doi: 10.1097/01.tp.0000296103.34735.b8.
Bensinger WI, Baker DA, Buckner CD, Clift RA, Thomas ED. Immunoadsorption for removal of A and B blood-group antibodies. N Engl J Med. 1981 Jan 15;304(3):160-2. doi: 10.1056/NEJM198101153040308.
Alexandre GP, Squifflet JP, De Bruyère M, et al. Present experiences in a series of 26 ABO-incompatible living donor renal allografts. Transplant Proc. 1987 Dec;19(6):4538-42.
Bannett AD, McAlack RF, Raja R, Baquero A, Morris M. Experiences with known ABO-mismatched renal transplants. Transplant Proc. 1987 Dec;19(6):4543-6.
Kumlien G, Ullström L, Losvall A, Persson LG, Tydén G. Clinical experience with a new apheresis filter that specifically depletes ABO blood group antibodies. Transfusion. 2006 Sep;46(9):1568-75. doi: 10.1111/j.1537-2995.2006.00927.x.
Terman DS, Tavel T, Petty D, Racic MR, Buffaloe G. Specific removal of antibody by extracorporeal circulation over antigen immobilized in collodion-charcoal. Clin Exp Immunol. 1977 Apr;28(1):180-8.
Copyright (c) 2020 A.I. Malik, R.O. Zohrabian